Nidogen-1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients

Baiwei Zhang1,*, Cheng Xu2,3,*, Junfeng Liu1, Jinsheng Yang4, Qinglei Gao2,3, Fei Ye1

1Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2Cancer Biology Research Center, Key Laboratory of the Ministry of Education, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4Department of Neurosurgery, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
*Equal contribution

Correspondence to: Fei Ye; email: feiye@tjh.tjmu.edu.cn
Keywords: NID1, glioma, basement membrane, apoptosis, temozolomide
Received: August 8, 2020 Accepted: February 16, 2021 Published: March 18, 2021

ABSTRACT

We investigated the prognostic significance of nidogen-1 (NID1) in glioma. Oncomine, GEPIA, UALCAN, CCGA database analyses showed that NID1 transcript levels were significantly upregulated in multiple cancer types, including gliomas. Quantitative RT-PCR analyses confirmed that NID1 expression was significantly upregulated in glioma tissues compared to paired adjacent normal brain tissue samples (n=9). NID1 silencing enhanced in vitro apoptosis and the temozolomide sensitivity of U251 and U87-MG glioma cells. Protein-protein interaction network analysis using the STRING and GeneMANIA databases showed that NID1 interacts with several extracellular matrix proteins. TIMER database analysis showed that NID1 expression in low-grade gliomas was associated with tumor infiltration of B cells, CD4+ and CD8+ T cells, macrophages, neutrophils, and dendritic cells. Kaplan-Meier survival curve analysis showed that low-grade gliomas patients with high NID1 expression were associated with shorter overall survival. However, NID1 expression was not associated with overall survival in glioblastoma multiforme patients. These findings demonstrate that NID1 expression in glioma tissues is associated with overall survival of low-grade glioma patients and temozolomide sensitivity. NID1 is thus a potential prognostic biomarker and therapeutic target in low-grade glioma patients.

INTRODUCTION

Glioma is a highly malignant brain tumor with poor prognosis despite the availability of conventional therapeutic options including surgical excision followed by adjuvant radio-chemotherapy [1, 2]. Molecular targeted therapy has emerged as an important therapeutic option for several cancers because it provides greater specificity compared to traditional chemo-radiotherapy [3]. However, effective targeted therapies are still not available for glioma patients despite identification of several prognostic biomarkers [4, 5]. Hence, there is an urgent need to identify new and more effective therapeutic targets in gliomas. The abnormally high expression of NID1, which is widely discussed in various types of other cancers including ovarian cancer, non-small cell lung cancer and hepatocellular carcinoma [6–8], in glioma is uncovered through the differently expressed genes (DEGs) analysis between normal and cancer of brain/central nervous
NID1 is a 150 KDa glycoprotein belonging to the Nidogen (also termed entactin) family and is an essential component of the basement membrane [9]. NID1 consists of three (G1-G3) globular domains—one flexible linker domain that connects G1 and G2 domains, and one rod-like domain that separates G2 and G3 domains [10]. NID1 is secreted by mesenchymal cells and deposited between epithelial cells [11, 12]. NID1 is sensitive to various proteases and plays a significant role in basement membrane remodeling [13]. NID2 is a paralog of NID1 with complementary functions [14]. NID1 plays a significant role in the formation and stabilization of the basement membrane network, wound healing, cell adhesion, chemotaxis, and phagotrophy [15–17].

NID1 is also regarded as an oncogene in many cancer types. NID1 promotes epithelial-mesenchymal transition (EMT) and metastasis in ovarian cancer [6]. NID1 enhances adhesion of ETV5-overexpressing endometrial cancer cells to the extracellular matrix (ECM) and promotes their proliferation and migration [18]. Serum NID1 levels are elevated in non-small cell lung cancer (NSCLC) patients compared to the healthy controls [7]. NID1-enriched vesicles secreted by hepatocellular carcinoma (HCC) cells facilitate extrahepatic HCC metastasis [8]. These findings suggest that NID1 plays a crucial role in tumorigenesis. However, the role of NID1 in glioma is not known. Therefore, in this study, we investigated the relationship between NID1 expression and prognosis of glioma patients.

RESULTS

NID1 is overexpressed in several cancers

We analyzed NID1 expression in 15 different kinds of cancers using the Oncomine database with P ≤ 1E-4, fold change ≥ 2, and gene rank in the top10% as threshold parameters. NID1 expression was significantly higher in multiple cancer types compared to their corresponding normal tissues, as reported in 25 unique cancer studies including 6 studies related to brain and CNS tumors (Figure 1A). The detailed information of the 6 brain tumor-related studies is shown in Table 1. The analysis of 5 studies related to brain and CNS tumors (the sixth study was a TCGA dataset) showed that NID1 was overexpressed in brain tumor tissues compared to the corresponding normal brain tissues (Figure 1B). NID1 was significantly upregulated in glioblastoma (Murat and Sun brain datasets), anaplastic astrocytoma (Sun brain dataset), and oligodendroglioma (French and Sun brain datasets) tissues compared to the corresponding normal tissue samples (Figure 1C–1G).

NID1 is overexpressed in several pan-cancer tissue datasets from UALCAN and GEPIA databases

We analyzed NID1 expression in pan-cancer tissues using UALCAN and GEPIA databases (Supplementary Table 1). GEPIA database analysis showed that NID1 expression levels were significantly higher in cancers such as low grade glioma, glioblastoma multiforme, kidney renal clear cell carcinoma, head and neck squamous cell carcinoma, and others (Figure 2A). UALCAN database analysis also showed that NID1 expression was significantly higher in several cancer types compared to the corresponding normal tissues (Figure 2B).

NID1 overexpression in different grades of glioma

Next, we analyzed the expression of NID1 in various grades of gliomas. According to the World Health Organization (WHO) criteria, gliomas are classified into four grades—WHO grades I, II, III, and IV [19]. WHO grades I, II, and III are collectively called as low-grade gliomas (LGG), whereas, WHO grade IV is called glioblastoma multiforme (GBM) and is the most malignant type of glioma [20, 21]. GEPIA database analysis showed that NID1 transcript expression in the LGG and GBM tissues was significantly higher compared to the normal brain tissues (Figure 3A). CGGA database analysis also showed that NID1 expression was significantly increased in the higher glioma grades (Figure 3B). Furthermore, IDH mutant GBM tissues showed significantly lower NID1 expression than the IDH wild-type GBM tissues, but NID1 expression in IDH mutant and wild-type LGG tissues was similar (Figure 3C). Furthermore, qRT-PCR analysis of 9 pairs of glioma tissues and adjacent non-tumor brain tissues (Supplementary Table 2) showed that NID1 mRNA expression was significantly higher in 100% (9/9) of glioma tissues compared to the corresponding adjacent normal brain tissues (p<0.0001; Figure 3D).

NID1 protein expression in brain tissues of glioma patients

Next, we analyzed NID1 protein expression levels in the brains of normal healthy individuals and glioma patients using the HPA database. NID1 protein expression in the normal healthy adult brain tissue (for example, patient id: 2521) was moderate and restricted to the ECM-neuripil area and not detected in the endothelial cells, glial cells, and neuronal cells (Figure 3E; top). In the glioma patients (patient id: 3092)
Figure 1. NID1 is overexpressed in several cancers including different types of glioma. (A) Summary of NID1 expression analyses in multiple cancer types and their corresponding normal tissues. Note: P< 0.001 indicates statistical significance. Red color indicates high NID1 expression in the corresponding cancer and blue color indicates low NID1 expression in the corresponding cancer. (C–G) NID1 expression in (C) Murat brain (normal brain vs. glioblastoma), (D) French brain (normal brain vs. anaplastic oligodendroglioma), (E) Sun brain (normal brain vs. glioblastoma), (F) Sun brain (normal brain vs. anaplastic astrocytoma), and (G) Sun brain (normal brain vs. oligodendroglioma) datasets are shown. Note: P<0.01 indicates statistical significance; NID1 was among the top 1% overexpressed genes in all five different grades of glioma.
Table 1. NID1 expression data from six studies that analyzed brain and CNS cancer samples.

| Datasets (n)          | Study object                                  | Fold change | t     | P          | Ref |
|-----------------------|-----------------------------------------------|-------------|-------|------------|-----|
| Murat Brain (84)      | Glioblastoma vs. Normal                       | 10.988      | 31.646| 5.40E-48   | [22]|
| French Brain (33)     | Anaplastic Oligodendroglioma vs. Normal       | 7.491       | 10.191| 4.83E-11   | [23]|
|                       | Glioblastoma vs. Normal                       | 5.818       | 133.786| 4.27E-23   |     |
| Sun Brain (180)       | Anaplastic Astrocytoma vs. Normal             | 4.097       | 8.582 | 7.17E-10   | [24]|
|                       | Oligodendroglioma vs. Normal                  | 3.083       | 7.216 | 2.37E-10   |     |
| TCGA Brain (557)      | Brain Glioblastoma vs. Normal                 | 9.518       | 22.006| 7.26E-11   | [-] |

Figure 2. NID1 expression in pan-cancer tissues from GEPIA and UALCAN databases. (A) NID1 transcript levels in paired tumor and normal tissue samples from the GEPIA database. Red dots represent NID1 expression in tumor samples; green dots indicate NID1 expression in the corresponding normal tissues; black line indicates median NID1 expression; tumor names highlighted in green indicate NID1 downregulation; tumor names highlighted in red indicate NID1 upregulation; tumor names highlighted in black indicate normal NID1 expression; T= tumor tissue; N= normal tissue. (B) Validation of NID1 expression levels in different cancers from the UALCAN database. The red boxes represent NID1 expression in tumor tissues and blue boxes represent NID1 expression in the corresponding normal tissues.
Figure 3. NID1 mRNA and protein expression in different grades of gliomas. (A) NID1 transcript expression levels in low-grade glioma (LGG; red; n=518), glioblastoma multiforme (GBM; red; n=163) and corresponding normal brain tissues (black; n=207) from the GEPIA datasets. (B) NID1 expression levels in different grades of glioma (WHO grades II, III, and IV) from the CCGA dataset. As shown, NID1 expression levels are significantly higher in WHO grades III and IV compared to WHO grade II. (C) NID1 expression levels in LGG and GBM patients belonging to IDH mutant and wild-type genotypes from the CCGA datasets. As shown, IDH mutant GBM patients show lower NID1 levels compared to the IDH wild-type GBM patients. NID1 levels in IDH mutant and wild-type LGG patients are comparable and not statistically significant. (D) NID1 expression is upregulated in all 9 glioma tissue samples compared to their corresponding normal brain tissue samples. Red circles represent glioma tissues and blue circles represent normal brain tissues. Higher ΔCt value represents lower NID1 expression. (E) Representative IHC-stained brain section images from the HPA database show NID1 expression in normal healthy individual (patient i.d. 2521) and glioma patient (patient id: 3092). Blue staining represents anti-NID1 antibody staining. Note: * P<0.05; ** P<0.01; *** P<0.001; **** P<0.0001.
however, heterogeneous cytoplasmic or membranous NID1 protein expression was observed in the ECM area of both the normal brain neuropils and the tumor cells (Figure 3E-bottom). Moreover, NID1 protein staining was positive in the highly malignant glioma cells, but the staining intensity in the glioma cells (75%-25%) was lower compared to the normal neuropil area (>75%; Figure 3E-bottom). These results suggested that NID1 may be involved in the ECM remodeling around the glioma tissue.

Silencing of NID1 promotes apoptosis and TMZ sensitivity of U87-MG and U251 glioma cells

NID1 is a glycoprotein that is required for the stability of the basement membrane [25]. Therefore, we analyzed if NID1 regulates glioma cell apoptosis. RT-PCR and western blot analysis confirmed that NID1 expression was significantly reduced in the si-NID1-transfected U87-MG and U251 glioma cells compared to the corresponding si-NC-transfected glioma cells (Figure 4A, 4B). The apoptotic rate was significantly increased in the NID1-silenced U87-MG and U251 glioma cells compared to the corresponding si-NC-transfected controls (P<0.05, Figure 4C). Moreover, we also compared the apoptosis rate between si-NID1 group and si-NC group with or without TMZ treatment, a significant increase of apoptosis rate in si-NID1 group was revealed compared to si-NC group (P<0.05, Figure 4D), indicating that NID1-silencing could be an effective approach to increased TMZ sensitivity of glioma cells. Hence, this suggested that NID1 is a potential therapeutic target in glioma.

Functional enrichment analysis of top 100 NID1-related genes

We performed gene ontology (GO) and pathways (KEGG/Canonical) analyses of the top100 NID1-related genes identified from the GBM data in the GEPIA database (Supplementary Table 3). NID1-related genes were enriched in GO terms (biological processes) and pathways related to cell-substrate adhesion, cellular response to tumor necrosis factor, Rho protein signal transduction, eye development, drug metabolism– Cytochrome P450 (KEGG pathway), NABA core matrisome, NABA matrisome associated, and NABA ECM affiliated gene sets ( Canonical pathway; Figure 5A, 5B).

PPI network analysis of NID1 and its interacting partners

We used the STRING database to construct a protein-protein interaction (PPI) network of NID1-associated proteins that included proteins such as HSPG2, matrix metalloproteinase (MMP), and laminin subunit proteins such as LAMA1, LAMC1, LAMB1, and others (Figure 6A). Furthermore, GeneMANIA database analysis showed that NID1 interacted with NID2 (paralog of NID1), collagen subunits such as COL15A1, COL4A1, COL18A1, and COL3A1, and integrins such as ITGA3 and ITGB1, all of which were components of the basement membrane (BM) or extracellular matrix (ECM) (Figure 6B).

NID1 expression is associated with immune cell infiltration in glioma

Basement membrane is a thin layer of the extracellular matrix (ECM) that is required for cellular function and tissue integrity [26]. In cancers, the extracellular tumor microenvironment, participates in the development and progression of tumors [27, 28]. Therefore, we analyzed the relationship between NID1 expression levels and the status of immune cell infiltration in LGG and GBM tissues using the TIMER database. The results showed significant correlation between NID1 expression levels and the infiltration levels of immune cells such as B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic in LGG tissues, however, which is unobvious in GBM tissues. (Figure 7).

High NID1 expression correlates with poor overall survival of LGG patients

Next, we evaluated the prognostic value of NID1 expression in glioma patients from the UALCAN and GEPIA databases. Kaplan-Meier survival curve analysis showed that high NID1 expression correlated with worse overall survival of LGG patients (Figure 8A, 8C). However, we did not observe significant correlation between NID1 expression levels and overall survival of GBM patients (Figure 8B, 8D). Furthermore, we analyzed the survival data of glioma patients in the TCGA database (UCSC Xena browser) after excluding cases of tumor recurrence tumor and those without survival time. We sub-divided TCGA-glioma patients into high- and low-NID1 expression groups based on median NID1 expression levels. Kaplan–Meier survival curve analysis showed that overall survival (OS) of LGG patients with low NID1 expression was significantly higher compared to LGG patients with high NID1 expression (P = 0.035; Figure 8E). However, NID1 expression levels did not correlate with survival in GBM patients (P=0.283; Figure 8F). These results suggested that high NID1 expression was associated with worse OS in LGG patients.

DISCUSSION

Basement membranes are thin sheets of specialized extracellular matrix (ECM) that provide structural
Figure 4. NID1 silencing in U87-MG and U251 glioma cells enhanced apoptosis and sensitivity to TMZ. (A) QRT-PCR analysis shows NID1 mRNA levels in si-NID1- and si-NC-transfected U251 and U87-MG glioma cell lines. (B) Representative western blot shows NID1 protein levels in si-NID1- and si-NC-transfected U251 and U87-MG glioma cell lines. (C) Representative FACS plots and histograms show percentage apoptosis in si-NID1- and si-NC-transfected U251 and U87-MG glioma cells based on AnnexinV-FITC/PI staining. (D) Representative FACS plots and histograms show percentage apoptosis in si-NID1- and si-NC-transfected U251 and U87-MG glioma cells treated with or without TMZ. As shown, NID1 silencing improved temozolomide (TMZ) sensitivity in glioma cells. Note: * P<0.05; ** P<0.01; *** P<0.001; **** P<0.0001.
support to cells and tissues, and also regulate cellular proliferation, adhesion, migration, differentiation, and survival [25, 26, 29–31]. Basement membranes play a significant role in cellular signaling, normal growth and development of tissues and organs, and human diseases including cancers [32]. The basement membrane consists of various glycoproteins and proteoglycan protomers including laminin, collagen IV, heparan sulphate proteoglycans such as perlecan and agrin, nidogen/entactin, fibulin like BM-90, and BM-40 (basement membrane protein of 40 kDa) [25, 26, 29, 33]. Laminins are heterotrimeric proteins that form a cross shaped structure with one long arm and three short arms, and are made up of one of the five α chains, one of the three β chains, and one of the three γ chains; the N-terminal regions of the α, β, and γ chains (the short arm) assemble to form ternary nodes that are involved in forming the cell-associated network [34–37]. Collagen IV (type IV collagen) is only found in the basement membranes and consists of six highly homologous but genetically distinct α-chains (α1 to α6), an N-terminal 7S domain, a central collagenous triple helix domain, and a C-terminal non-collagenous (NC1) domain [38]. The α-chains intertwine into a triple helix through the collagenous domain that contains Gly-X-Y amino-acid triple repeats; collagen IV molecules assemble into networks through their N-terminal and C-terminal end-domains [39–41]. The laminin-

---

**Figure 5. The top GO terms and pathways related to top 100 NID1-related genes in GBM tissues.** (A) Heatmap shows top GO terms and (KEGG/Canonical) pathways related to the top 100 NID1-related genes expressed in GBM tissues. The -log10P values are plotted on the X-axis. (B) The network of enriched gene sets representing the top 100 NID1-related genes expressed in GBM tissues.
collagen IV- networks in the basement membranes are connected with each other and stabilized by NID1 and other basement membrane proteins [25, 32, 42, 43]. Heparin sulfate proteoglycans (HSPGs) are glycoproteins with one or more heparin sulfate chains; basement membranes contain perlecán and agrin HSPGs, which increase the volume of extracellular matrix [32]. Tysnes et al. reported that in vitro glioma cell migration was stimulated by laminin, fibronectin, and collagen type IV [44]. Ohlund et al. reported that high circulating levels of collagen type IV in post-operative pancreatic cancer patients were associated with rapid relapse and poor survival rates [45]. Agrin plays a significant role in maintaining the blood-brain barrier (BBB), and its deficiency leads to brain edema in GBM patients [46].

NID1 is expressed in normal brain tissues and is required for maintaining normal synaptic plasticity and network excitability [47]. Nonsense mutations in the

---

**Figure 6.** PPI networks of NID1 and its interacting protein partners. (A) PPI network constructed using the STRING database shows NID1 and the NID1-interacting proteins. The line thickness indicates strength of interaction between any two proteins. (B) GeneMANIA database analysis shows that NID1 interacts with ECM proteins such as HSPG2, LAMC1, and others.

**Figure 7.** Higher NID1 expression correlates with increased tumor infiltration of multiple immune cell types. TIMER database analysis shows correlation between NID1 expression levels in LGG (top) and GBM (bottom) patient tissues and tumor infiltration levels of immune cell types, namely, B cells, CD8+ T cells, CD4+T cells, macrophages, neutrophils, and dendritic cells. Each dot corresponds to a glioma patient (LGG or GBM). The blue line represents median levels of tumor-infiltrated immune cells.
Figure 8. NID1 expression correlates with overall survival of LGG patients. (A, B) Kaplan-Meier survival curves show overall survival of low- and high-NID1-expressing LGG and GBM patients from the UALCAN database. (C, D) Kaplan-Meier survival curves show overall survival of low- and high-NID1-expressing LGG and GBM patients from the GEPIA database. HR refers to hazard ratio. (E, F) Kaplan-Meier survival curves show overall survival of low- and high-NID1-expressing LGG and GBM patients from the TCGA database. Note: Blue represents low NID1 expression; red represents high NID1 expression.
NID1 gene are associated with autosomal dominant Dandy-Walker malformation and occipital cephaloceles (ADDWOC), a disorder characterized by normal neurological development but variable cerebellar hypoplasia, meningeal anomalies, and occipital skull defects [48–50]. NID1 also promotes EMT and metastasis in ovarian cancer [6]. Moreover, cathepsin degradation of Nid-1 is strongly associated with NSCLC [7]. Mao et al. reported that NID1-enriched extracellular vesicles derived from HCC cells facilitate colonization of tumor cells and extra-hepatic metastasis by activating pulmonary fibroblasts to secrete TNFR1 [8]. Our study showed that NID1 expression was significantly higher in glioblastoma, anaplastic astrocytoma, and oligodendroglioma compared to the normal brain tissues and cells using glioma datasets from Oncomine, UALCAN, and GEPIA databases. This data was confirmed by qRT-PCR analysis of 9 paired glioma and normal brain samples. We also showed that NID1 silencing induced glioma cell apoptosis and increased sensitivity of glioma cells to TMZ. These data suggest that NID1 plays a key role in glioma cell survival and TMZ resistance, although the underlying mechanisms are not known and require further investigations.

Immunohistochemical staining data in the HPA database showed that NID1 staining in the brain tissues of healthy individuals and patients with high-grade glioma was restricted to the ECM area. Furthermore, NID1 protein levels in highly malignant glioma were significantly lower than in the normal neuropils. That is because the interactions between ECM and the glioma cells are highly complex [51]. Glioblastoma multiforme (GBM; WHO grade IV astrocytoma) is the most malignant astrocyte tumor [52]. A widely accepted speculation is that malignant tumors possess a less differentiated or a progenitor state of their cellular origin [53], which may result in loss of primary brain cells components and structural features, like BM dissociation. Furthermore, MMPs protein levels in brain glioma tissue are elevated with the increasing pathological grades [54–56]. MMPs promote glioma cell infiltration by cleaving glycoproteins and adhesion proteins in the ECM [57–59]. Nidogen is hypersensitive to proteolytic cleavage and is protected from hydrolysis by its interaction with laminin [13, 15, 60]. The weak NID1 protein staining in the brain tissue of glioma patients suggests that NID1 is cleaved during glioma progression. Hence, our data suggests that NID1 regulates malignant transformation of glioma because it maintains basement membrane integrity.

We constructed PPI network to identify NID1-interacting proteins. NID1 interacted with several ECM components such as laminin, HSPG2 (Perlecan), and MMPs. The amino acid sequences of murine nidogen suggest that it binds to laminin, collagen IV, and cells through multiple domains [61]. Aumailley et al. demonstrated that nidogen is an integral part of the ternary complex between laminin and collagen IV in the basement membrane [62]. High-affinity binding of NID1 to laminin γ1 chain is critical for the formation of basement membrane [63]. Haltfer et al. reported that deletion of NID1 binding site in laminin γ1 chain caused defects in the pial basement membrane and disrupted neuronal migration and proper cortical development [64]. NID1 also played an indirect role in integrin signaling by being an integral part of the laminin-NID1 complex that anchored α7β1 integrin, one of the cell surface integrin receptors [65]. The high-affinity interaction between NID1 and Perlecan (HSPG2) also contributed to basement membrane function and stabilization [66, 67]. Titz et al. demonstrated that MMP-19 preferentially cleaved out the G3 globular domain of NID1, which contained the binding site for the γ1 chain of laminin-1 and collagen IV, thereby abolishing its ability to cross-link ECM proteins [68]. Hence, NID1 plays an integral role in extracellular signaling and structural integrity of ECM.

We also demonstrated that LGG patients with low NID1 expression showed significantly higher OS rates. However, NID1 expression did not correlate with OS of GBM patients. Since interactions between ECM components and cells are complex, further studies are necessary to investigate the distinct roles of NID1 in LGG and GBM.

In conclusion, our study shows that NID1 is up-regulated in glioma tissues. Functional enrichment and PPI network analyses demonstrate that NID1 interacts with several ECM proteins, thereby confirming its role in stabilizing the basement membrane. NID1 silencing promotes in vitro apoptosis and TMZ sensitivity of glioma cells. Furthermore, low NID1 expression in LGG patients correlates with significantly higher overall survival. These findings suggest that NID1 plays a significant role in glioma development and is a potential therapeutic target in glioma patients.

**MATERIALS AND METHODS**

**Bioinformatics analysis**

The Oncomine (https://www.oncomine.org) database [69] was used to analyze NID1 transcript levels in several cancer types including gliomas and their corresponding normal tissues with P-value <0.05 and fold change ≥2 as threshold parameters.
Gene Expression Profiling Interactive Analysis (GEPIA; http://gepia.cancer-pku.cn/) is a comprehensive web-based tool that provides interactive and customizable functions to analyze differential gene expression, patient survival, similar gene filtering, and correlation analysis using RNA sequencing data from TCGA and GTEx datasets [70]. We used the GEPIA database to evaluate NID1 expression profiles in several tumors, identify top 100 genes that correlate with NID1 expression, and compare survival of glioma patients with high and low NID1 expression.

UALCAN (http://ualcan.path.uab.edu) is a comprehensive and interactive web portal with TCGA level 3 RNA-seq and clinical data for 31 cancer types, and is used to determine differential expression and prognostic value of target genes in cancer [71]. In this study, we used the UALCAN database to verify NID1 expression in pan-cancer tissues and evaluate prognostic value of NID1 in glioma patients.

Chinese Glioma Genome Atlas (CGGA) (http://www.cgga.org.cn/) is a user-friendly database with functional genomic data for approximately 2,000 primary and recurrent glioma samples from Chinese cohorts. The analysis tools in the CGGA database allow access to gene mutational data, mRNA and microRNA expression data, DNA methylation profiles, as well as survival and correlation analysis of specific glioma types [72]. We used the CGG database to analyze NID1 expression levels in different glioma grades.

Human Protein Atlas (HPA) (https://www.proteinatlas.org) is a database that contains maps of all known human proteins in cells, tissues, and organs by integration of data from various omics technologies, including antibody-based imaging, transcriptomics, systems biology, and mass-spectrometry-based proteomics [73–76]. In this study, we used HPA database to determine NID1 protein expression in gliomas and normal brain tissues.

Metascape (http://metascape.org) is a web-based portal that combines functional enrichment, interactome analysis, gene annotation, and membership search from over 40 independent knowledge-bases into a single integrated portal [77]. We performed Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses using this portal to comprehensively annotate a list of 100 NID1-related genes.

We constructed Protein-Protein interaction (PPI) networks of NID1 and its interacting proteins using STRING and GeneMANIA databases. The STRING database (http://string.embl.de/) comprehensively integrates protein-protein interaction information from all the available sources complemented with computational predictions in order to achieve a comprehensive global network that includes direct and indirect protein interactions [78, 79]. Gene MANIA (http://www.genemania.org) is a user-friendly web platform to find functionally similar genes using extensive genomic and proteomic data [80].

Tumor Immune Estimation Resource (TIMER) (http://cistrome.shinyapps.io/timer/) database is used to characterize association between tumor infiltration of several immune cell types and other disease-related factors including gene expression, clinical outcomes, somatic mutations, and somatic copy number alterations [81]. In this study, we analyzed the association between NID1 expression levels and infiltration status of six different immune cell types in gliomas (LGG and GBM) after adjusting for tumor purity using Spearman correlation coefficient (COR) and P-values. COR>0 indicated positive correlation and COR<0 indicated negative correlation; P <0.05 was considered statistically significant.

We also downloaded RNA sequencing data and corresponding clinical information of the glioma patient samples from The Cancer Genome Atlas (TCGA) database using the University of California Santa Cruz (UCSC) Xena browser (http://xena.ucsc.edu/) and analyzed prognostic significance of NID1 gene expression with OS of glioma patients by evaluating Kaplan-Meier survival curves [82].

Glioma cell lines and cell culture

The U87-MG and U251 glioma cell lines were purchased from American Type Culture Collection (ATCC, Rockville, MD, USA) and cultured in Dulbecco’s Modified Eagle Medium (DMEM; Gibco, NY, USA) containing 10% fetal bovine serum (FBS; BI, Israel), penicillin (100 units/ml), and streptomycin (100 µg/ml) in a humidified incubator maintained at 5% CO₂ and 37°C.

NID1 silencing and temozolomide sensitivity

We purchased NID1-specific and non-specific control (NC) siRNAs from TsingKe Biotechnology (Beijing, China) and transfected them into glioma cell lines using lipofectamine 2000 (Invitrogen, USA) according to the manufacturer’s instructions. We also tested temozolomide (TargetMol; Target Molecule Corp, Boston, MA, USA) sensitivity of siNID1- and si-NC-transfected glioma cells. In brief, groups of si-NID1- and si-NC-transfected glioma cells were treated with TMZ (200µM, 24 hours), after that, the apoptosis rates
of si-NID1 group and si-NC group with or without TMZ treatment were calculated respectively.

**Glioma patient samples**

We obtained fresh glioma and adjacent normal brain tissue samples from 9 patients that underwent surgery at the Department of Neurosurgery, Tongji Hospital, Wuhan. We obtained signed written consent from all patients. This study was conducted according to the protocol and guidelines approved by the Tongji hospital Institutional Review Board. The samples were immediately incubated with Trizol (Takara Bio, Japan) at 0°C in a specimen-box and stored at -80°C. Total RNA was extracted within 12 h after sample isolation.

**Western blot**

The si-NID1 and si-NC transfected glioma cells were lysed in pre-chilled radioimmunoprecipitation (RIPA) buffer (Servicebio, Wuhan, China) containing protease inhibitor PMSF (1:100) and phosphatase inhibitor cocktail (1:100) at 0°C for 30 min. The protein concentrations were measured using BCA protein assay kit (Beyotime, Shanghai, China). Equal amounts of protein samples (40 μg) were separated by 10% SDS-PAGE and transferred onto PVDF membranes. The membranes were blocked with 5% bovine serum albumin (BSA) for 1 h at room temperature and incubated overnight at 4°C with primary antibodies against NID1 (1:1000;AF2570-S; R&D Systems, MN, USA) and GAPDH (1:1000;ab9485;Abcam, UK). Then, the membranes were washed thrice with TBST buffer (25 mM Tri-HCl, pH7.5, 137 mM NaCl, 2.7 mM KCl, and 0.05% Tween-20) and incubated with HRP-conjugated anti-goat IgG (1:3000; Servicebio, Wuhan, China) or HRP-conjugated anti-rabbit IgG (1:5000; Antgene, Wuhan, China) for 1 h at room temperature. The membranes were then washed thrice with TBST. The blots were developed using the Enhanced chemiluminescence kit (ECL, Bio-Rad, CA, USA). The protein bands were quantified by Image J software.

**Real-time quantitative polymerase chain reaction**

Total RNA of primary glioma and adjacent normal brain tissue samples were extracted with Trizol (Takara Bio, Japan) according to the manufacturer’s protocols. Then, cDNAs were synthesized from 10 μl of total RNA using HiScript® II Q RT SuperMix Kit (Vazyme, Nanjing, China). Quantitative real-time PCR was performed in the CFX Connect Real-Time System (Bio-Rad Laboratories, Berkeley, CA, USA) using ChamQ™ Universal SYBR® qPCR Master Mix (Vazyme, Nanjing, China) according to the manufacturer’s instructions. The qPCR primer sequences were as follows:

Human NID1 (forward), 5'-GACAGCGTGTTCTGTCGTCGTA-3'; Human NID1 (reverse), 5'-ACACCTCCCGATGGACAAAG-3'; Human GAPDH (forward), 5'-GATCCTGGGCTACACTGAG-3'; Human GAPDH (reverse), 5'-TAACGGAAGTGTGCGTGAAG-3'.

The samples were analyzed independently thrice. The real-time PCR protocol was: 1 cycle of 95°C for 90 s followed by 40 cycles of 95°C for 10 s and 60°C for 60 s. The mean cycle threshold (Ct) values for NID1 (target gene) and GAPDH (endogenous control) were determined. Relative levels of NID1 mRNA expression were quantified using the 2−ΔΔCt method.

**Apoptosis assay**

The glioma cells after treatments were washed twice in pre-chilled PBS, resuspended in 100 μl of binding buffer, and stained with the Annexin V-FITC/propidium iodide kit (BD Biosciences, NJ, USA) in the dark according to manufacturer’s recommendations. Then, the samples were analyzed in a FACS Calibur (Beckman Coulter, USA). We collected a minimum of 10,000 cells for each sample. The percentages of apoptotic cells (Annexin V-FITC+ PI+ plus Annexin V-FITC+ PI- cells) were determined using the FlowJo software (Treestar, Ashland, OR, USA).

**Statistical analysis**

The data was analyzed using paired student’s t-test and chi-square test. Statistical analysis was performed using GraphPad Prism 8.0 (GraphPad Software, CA, USA) and SPSS statistical software version 25.0 (IBM, Armonk, NY, USA). Kaplan-Meier survival curve analysis was used to evaluate overall survival of glioma patients with high and low NID1 expression. The differences between groups were assessed by log-rank test. P<0.05 was considered statistically significant. All experiments were repeated at least thrice.

**Abbreviations**

NID1: Nidogen-1; TMZ: Temozolomide; DEGs: Differently expressed genes; CNS: Central nervous system; EMT: Epithelial-mesenchymal transition; ECM: The extracellular matrix; NSCLC: Non-small cell lung cancer; HCC: Hepatocellular carcinoma; GEPIA: Gene Expression Profiling Interactive Analysis; CGGA: Chinese Glioma Genome Atlas; HPA: Human Protein Atlas; OS: Overall survival; WHO: World Health Organization; LGG: low-grade glioma; GBM: Glioblastoma multiforme; siRNA: small interfering
RNA; TPM: Transcripts Per Million; GO: gene ontology; KEGG: Kyoto encyclopedia of genes and genomes; PPI: Protein-protein interaction; The Cancer Genome Atlas; TCGA; HR: Hazard ratio; BMS/BM: Basement membranes/ basement membrane; ADDWOC: Autosomal dominant Dandy-Walker malformation and occipital cephaloceles; BBB: Blood-brain barrier.

AUTHOR CONTRIBUTIONS

Fei Ye, Cheng Xu and Baiwei Zhang designed the research; Baiwei Zhang, and Cheng Xu performed the experiments and analyzed the data with Junfeng Liu and Jinsheh Yang; Fei Ye, Junfeng Liu and Baiwei Zhang collected the fresh glioma samples; Baiwei Zhang and Cheng Xu wrote the manuscript; Qinglei Gao and Fei Ye supervised the project. All authors approved the final manuscript.

ACKNOWLEDGMENTS

The authors thank all public databases used in this study. The authors also thank all the glioma patients who provided samples for the experiments in this study.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

FUNDING

This work was supported by funds from the Natural Science Foundation of Hubei Province (Grant No. 2019CFB453).

REFERENCES

1. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kailey T, et al. NCCN guidelines insights: central nervous system cancers, version 1.2017. J Natl Compr Canc Netw. 2017; 15:1331–45. https://doi.org/10.6004/jnccn.2017.0166 PMID:29118226

2. Chen R, Smith-Cohn M, Cohen AL, Colman H. Glioma subclassifications and their clinical significance. Neurotherapeutics. 2017; 14:284–97. https://doi.org/10.1007/s13311-017-0519-x PMID:28281173

3. Bedard PL, Hyman DM, Davids MS, Siu LL. Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet. 2020; 395:1078–88. https://doi.org/10.1016/S0140-6736(20)30164-1 PMID:32222192

4. Lapointe S, Perry A, Butowski NA. Primary brain tumours in adults. Lancet. 2018; 392:432–46. https://doi.org/10.1016/S0140-6736(18)30990-5 PMID:30060998

5. Le Rhun E, Preussner M, Roth P, Reardon DA, van den Bent M, Wen P, Reifenberger G, Weller M. Molecular targeted therapy of glioblastoma. Cancer Treat Rev. 2019; 80:101896. https://doi.org/10.1016/j.ctrv.2019.101896 PMID:31541850

6. Zhou Y, Zhu Y, Fan X, Zhang C, Wang Y, Zhang L, Zhang H, Wen T, Zhang K, Huo X, Jiang X, Bu Y, Zhang Y. NID1, a new regulator of EMT required for metastasis and chemoresistance of ovarian cancer cells. Oncotarget. 2017; 8:33110–21. https://doi.org/10.18632/oncotarget.16145 PMID:28416770

7. Willumsen N, Bager CL, Leeming DJ, Bay-Jensen AC, Karsdal MA. Nidogen-1 degraded by cathepsin S can be quantified in serum and is associated with non-small cell lung cancer. Neoplasia. 2017; 19:271–78. https://doi.org/10.1016/j.neo.2017.01.008 PMID:28282545

8. Mao X, Tey SK, Yeung CL, Kwong EM, Fung YM, Chung CY, Mak LY, Wong DK, Yuen MF, Ho JC, Pang H, Wong MP, Leung CO, et al. Nidogen 1-enriched extracellular vesicles facilitate extrahepatic metastasis of liver cancer by activating pulmonary fibroblasts to secrete tumor necrosis factor receptor 1. Adv Sci (Weinh). 2020; 7:2002157. https://doi.org/10.1002/advs.202002157 PMID:33173740

9. Durkin ME, Chakravarti S, Bartos BB, Liu SH, Friedman RL, Chung AE. Amino acid sequence and domain structure of entactin. Homology with epidermal growth factor precursor and low density lipoprotein receptor. J Cell Biol. 1988; 107:2749–56. https://doi.org/10.1083/jcb.107.6.2749 PMID:3264556

10. Fox JW, Mayer U, Nischt R, Aumailley M, Reinhardt D, Wiedemann H, Mann K, Timpl R, Krieg T, Engel J. Recombinant nidogen consists of three globular domains and mediates binding of laminin to collagen type IV. EMBO J. 1991; 10:3137–46. PMID:1717261

11. Hogan BL, Taylor A, Kurkinen M, Couchman JR. Synthesis and localization of two sulphated glycoproteins associated with basement membranes and the extracellular matrix. J Cell Biol. 1982; 95:197–204.
12. Ekblom P, Ekblom M, Fecker L, Klein G, Zhang HY, Kadoya Y, Chu ML, Mayer U, Timpl R. Role of mesenchymal nidogen for epithelial morphogenesis in vitro. Development. 1994; 120:2003–14. PMID: 7925005

13. Mayer U, Zimmermann K, Mann K, Reinhardt D, Timpl R, Nischt R. Binding properties and protease stability of recombinant human nidogen. Eur J Biochem. 1995; 227:681–86. https://doi.org/10.1111/j.1432-1033.1995.tb20188.x PMID: 7867626

14. Salmivirta K, Talts JF, Olsson M, Sasaki T, Timpl R, Ekblom P. Binding of mouse nidogen-2 to basement membrane components and cells and its expression in embryonic and adult tissues suggest complementary functions of the two nidogens. Exp Cell Res. 2002; 279:188–201. https://doi.org/10.1006/excr.2002.5611 PMID: 12243745

15. Dziadek M. Role of laminin-nidogen complexes in basement membrane formation during embryonic development. Experientia. 1995; 51:901–13. https://doi.org/10.1007/BF01921740 PMID: 7556571

16. Chung AE, Dong LJ, Wu C, Durkin ME. Biological functions of entactin. Kidney Int. 1993; 43:13–19. https://doi.org/10.1038/ki.1993.4 PMID: 8433553

17. Konrad L, Albrecht M, Renneberg H, Ulrix W, Hoeben E, Verhoeven G, Aumüller G. Mesenchymal entactin-1 (nidogen-1) is required for adhesion of peritubular cells of the rat testis in vitro. Eur J Cell Biol. 2000; 79:112–20. https://doi.org/10.1078/S0171-9335(04)70013-8 PMID: 10727019

18. Pedrola N, Devis L, Lauradó M, Campoy I, Martinez-Garcia E, Garcia M, Muinelo-Romay L, Alonso-Alconada L, Abal M, Alameda F, Mancebo G, Carreras R, Castellví J, et al. Nidogen 1 and Nuclear Protein 1: novel targets of ETV5 transcription factor involved in endometrial cancer invasion. Clin Exp Metastasis. 2015; 32:467–78. https://doi.org/10.1007/s10585-015-9720-7 PMID: 25924802

19. Diamandis P, Aldape K. World health organization 2016 classification of central nervous system tumors. Neurol Clin. 2018; 36:439–47. https://doi.org/10.1016/j.ncl.2018.04.003 PMID: 30072064

20. Steiber VW. Low-grade gliomas. Curr Treat Options Oncol. 2001; 2:495–506. https://doi.org/10.1007/s11864-001-0071-z PMID: 12057095

21. Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, et al. and Cancer Genome Atlas Research Network. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015; 372:2481–98. https://doi.org/10.1056/NEJMoa1402121 PMID: 26061751

22. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC, Hainfellner JA, Heppner FL, Dietrich PY, et al. Stem cell-related “self-renewal” signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J Clin Oncol. 2008; 26:3015–24. https://doi.org/10.1200/JCO.2007.15.7164 PMID: 18565887

23. French PJ, Swagemakers SM, Nagel JH, Kouwenhoven MC, Brouwer E, van der Spek P, Luider TM, Kros JM, van den Bent MJ, Sillevis Smitt PA. Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res. 2005; 65:11335–44. https://doi.org/10.1158/0008-5472.CAN-05-1886 PMID: 16357140

24. Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, Passaniti A, Menon J, Walling J, Bailey R, Rosenblum M, Mikkelsen T, Fine HA. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 2006; 9:287–300. https://doi.org/10.1016/j.ccr.2006.03.003 PMID: 16616334

25. Timpl R. Macromolecular organization of basement membranes. Curr Opin Cell Biol. 1996; 8:618–24. https://doi.org/10.1016/S0955-0674(96)80102-5 PMID: 8939648

26. Halfter W, Oertle P, Monnier CA, Camenzind L, Reyes-Lua M, Hu H, Candielo J, Labilloy A, Balasubramani M, Henrich PB, Plodinec M. New concepts in basement membrane biology. FEBS J. 2015; 282:4466–79. https://doi.org/10.1111/febs.13495 PMID: 26299746

27. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014; 15:1243–53. https://doi.org/10.1525/embr.201439246 PMID: 25381661

28. Eble JA, Niland S. The extracellular matrix in tumor progression and metastasis. Clin Exp Metastasis. 2019; 36:171–98. https://doi.org/10.1007/s10585-019-09966-1 PMID: 30972526
29. Poźni A, Yurchenco PD, lozzo RV. The nature and biology of basement membranes. Matrix Biol. 2017; 57–58:1–11. https://doi.org/10.1016/j.matbio.2016.12.009 PMID: 28040522
30. Paulsson M. Basement membrane proteins: structure, assembly, and cellular interactions. Crit Rev Biochem Mol Biol. 1992; 27:93–127. https://doi.org/10.3109/10409239209082560 PMID: 1309319
31. Dziadek M, Mitrangas K. Differences in the solubility and susceptibility to proteolytic degradation of basement-membrane components in adult and embryonic mouse tissues. Am J Anat. 1989; 184:298–310. https://doi.org/10.1002/aja.1001840405 PMID: 2526998
32. Sekiguchi R, Yamada KM. Basement membranes in development and disease. Curr Top Dev Biol. 2018; 130:143–91. https://doi.org/10.1016/bs.ctdb.2018.02.005 PMID: 29853176
33. Fukumoto S, Yamada Y. Review: extracellular matrix regulates tooth morphogenesis. Connect Tissue Res. 2005; 46:220–26. https://doi.org/10.1080/03008200500344017 PMID: 16546825
34. Timpl R, Brown JC. The laminins. Matrix Biol. 1994; 14:275–81. https://doi.org/10.1016/0945-053X(94)90192-9 PMID: 7827749
35. Hohenester E, Yurchenco PD. Laminins in basement membrane assembly. Cell Adh Migr. 2013; 7:56–63. https://doi.org/10.4161/cam.21831 PMID: 23076216
36. Ishihara J, Ishihara A, Fukunaga K, Sasaki K, White MJ, Briquez PS, Hubbell JA. Laminin heparin-binding peptides bind to several growth factors and enhance diabetic wound healing. Nat Commun. 2018; 9:2163. https://doi.org/10.1038/s41467-018-04525-w PMID: 29867149
37. Hohenester E. Structural biology of laminins. Essays Biochem. 2019; 63:285–95. https://doi.org/10.1042/EBC20180075 PMID: 31092689
38. Khoshnoodi J, Pedchenko V, Hudson BG. Mammalian collagen IV. Microsc Res Tech. 2008; 71:357–70. https://doi.org/10.1002/jemt.20564 PMID: 18219669
39. Hennet T. Collagen glycosylation. Curr Opin Struct Biol. 2019; 56:131–38. https://doi.org/10.1016/j.sbi.2019.01.015 PMID: 30822656
40. Wu Y, Ge G. Complexity of type IV collagens: from network assembly to function. Biol Chem. 2019; 400:565–74. https://doi.org/10.1515/hsz-2018-0317 PMID: 30864416
41. Knupp C, Squire JM. Molecular packing in network-forming collagens. Adv Protein Chem. 2005; 70:375–403. https://doi.org/10.1016/S0065-3233(05)70011-5 PMID: 15837521
42. Yurchenco PD. Basement membranes: cell scaffoldings and signaling platforms. Cold Spring Harb Perspect Biol. 2011; 3:a004911. https://doi.org/10.1101/cshperspect.a004911 PMID: 21421915
43. Timpl R, Dziadek M, Fujiwara S, Nowack H, Wick G. Nidogen: a new, self-aggregating basement membrane protein. Eur J Biochem. 1983; 137:455–65. https://doi.org/10.1111/j.1432-1033.1983.tb07849.x PMID: 6420150
44. Tysnes BB, Larsen LF, Ness GO, Mahesparan R, Edvardsen K, Garcia-Cabrera I, Bjerkvig R. Stimulation of glioma-cell migration by laminin and inhibition by anti-alpha3 and anti-beta1 integrin antibodies. Int J Cancer. 1996; 67:777–84. https://doi.org/10.1002/(SICI)1097-0215(19960917)67:6<777::AID-IJIC3>3.0.CO;2-O PMID: 8824548
45. Ohlund D, Lundin C, Ardnor B, Oman M, Naredi P, Sund M. Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer. Br J Cancer. 2009; 101:91–97. https://doi.org/10.1038/sj.bjc.6605107 PMID: 19491897
46. Rascher G, Fischmann A, Kröger S, Duffner F, Grote EH, Wolburg H. Extracellular matrix and the blood-brain barrier in glioblastoma multiforme: spatial segregation of tenasin and agrin. Acta Neuropathol. 2002; 104:85–91. https://doi.org/10.1007/s00404-002-0524-x PMID: 12070669
47. Vasudevan A, Ho MS, Weiergräber M, Nischt R, Schneider T, Lie A, Smyth N, Köhling R. Basement membrane protein nidogen-1 shapes hippocampal synaptic plasticity and excitability. Hippocampus. 2010; 20:608–20. https://doi.org/10.1002/hipo.20660 PMID: 19530222
48. Barkovich AJ, Millen KJ, Dobyns WB. A developmental and genetic classification for midbrain-hindbrain malformations. Brain. 2009; 132:3199–230.
49. McNiven V, Ito YA, Hartley T, Kernohan K, Miller E, Armour CM, and Care4Rare Canada. NID1 variant associated with occipital cephaloceles in a family expressing a spectrum of phenotypes. Am J Med Genet A. 2019; 179:837–41. https://doi.org/10.1002/ajmg.a.61095 PMID: 30773799

50. Darbo BW, Mahajan VB, Gakhar L, Skeie JM, Campbell E, Wu S, Bing X, Millen KJ, Dobyns WB, Kessler JA, Jalali A, Cremer J, Segre A, et al. Mutations in extracellular matrix genes NID1 and LAMC1 cause autosomal dominant Dandy-Walker malformation and occipital cephaloceles. Hum Mutat. 2013; 34:1075–79. https://doi.org/10.1002/humu.22351 PMID: 23674478

51. Ferrer VP, Moura Neto V, Mentlein R. Glioma infiltration and extracellular matrix: key players and modulators. Glia. 2018; 66:1542–65. https://doi.org/10.1002/glia.23309 PMID: 29464861

52. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Hum Mutat. 2007; 21:2683–710. https://doi.org/10.1002/humu.21597 PMID: 17974913

53. Dai C, Holland EC. Astrocyte differentiation states and glioma formation. Cancer J. 2003; 9:72–81. https://doi.org/10.1097/01.pdj.0000103040-200303000-00002 PMID: 12784872

54. Xie H, Xue YX, Liu LB, Wang P, Liu YH, Ying HQ. Expressions of matrix metalloproteinase-7 and matrix metalloproteinase-14 associated with the activation of extracellular signal-regulated kinase1/2 in human brain gliomas of different pathological grades. Med Oncol. 2011 (Suppl 1); 28:5433–38. https://doi.org/10.1007/s12032-010-9660-7 PMID: 20809186

55. Ma S, Pang C, Song L, Guo F, Sun H. The expression of ATF3, MMP-2 and maspin in tissue chip of glioma. Pak J Pharm Sci. 2015; 28:1059–63. PMID: 26051724

56. Ramachandran RK, Sørensen MD, Aaberg-Jessen C, Hermansen SK, Kristensen BW. Expression and prognostic impact of matrix metalloproteinase-2 (MMP-2) in astrocytomas. PLoS One. 2017; 12:e0172234. https://doi.org/10.1371/journal.pone.0172234 PMID: 28234925

57. VanMeter TE, Rooprai HK, Kibble MM, Fillmore HL, Broadus WC, Pilkington GJ. The role of matrix metalloproteinase genes in glioma invasion: co-dependent and interactive proteolysis. J Neurooncol. 2001; 53:213–35. https://doi.org/10.1023/A:1012280925031 PMID: 11716072

58. Ho IA, Chan KY, Ng WH, Guo CM, Hui KM, Cheang P, Lam PY. Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. Stem Cells. 2009; 27:1366–75. https://doi.org/10.1002/stem.50 PMID: 19489099

59. Lettau I, Hattermann K, Held-Feindt J, Brauer R, Sedlacek R, Mentlein R. Matrix metalloproteinase-19 is highly expressed in astroglial tumors and promotes invasion of glioma cells. J Neuropathol Exp Neurol. 2010; 69:215–23. https://doi.org/10.1097/NEN.0b013e3181ce9f67 PMID: 20142769

60. Paulsson M, Deutzmann R, Dziadek M, Nowack H, Timpl R, Weber S, Engel J. Purification and structural characterization of intact and fragmented nidogen obtained from a tumor basement membrane. Eur J Biochem. 1986; 156:467–78. https://doi.org/10.1111/j.1432-1033.1986.tb09605.x PMID: 3084254

61. Mann K, Deutzmann R, Aumaillé M, Timpl R, Raimondi L, Yamada Y, Pan TC, Conway D, Chu ML. Amino acid sequence of mouse nidogen, a multidomain basement membrane protein with binding activity for laminin, collagen IV and cells. EMBO J. 1989; 8:65–72. PMID: 2496973

62. Aumaillé M, Battaglia C, Mayer U, Reinhardt D, Nischt R, Timpl R, Fox JW. Nidogen mediates the formation of ternary complexes of basement membrane components. Kidney Int. 1993; 43:7–12. https://doi.org/10.1038/ki.1993.3 PMID: 8433572

63. Mayer U, Kohfeldt E, Timpl R. Structural and genetic analysis of laminin-nidogen interaction. Ann N Y Acad Sci. 1998; 857:130–42. https://doi.org/10.1111/j.1749-6632.1998.tb10113.x PMID: 9917838

64. Halfwerter W, Dong S, Yip YP, Willem M, Mayer U. A critical function of the pial basement membrane in cortical histogenesis. J Neurosci. 2002; 22:6029–40. https://doi.org/10.1523/JNEUROSCI.22-14-06029.2002 PMID: 12122064

65. Yurchenco PD, McKee KK, Reinhard JR, Ruegg MA. Laminin-deficient muscular dystrophy: molecular pathogenesis and structural repair strategies. Matrix Biol. 2018; 71:174–87.
66. Hopf M, Göhring W, Kohfeldt E, Yamada Y, Timpl R. Recombinant domain IV of perlecan binds to nidogens, laminin-nidogen complex, fibronectin, fibulin-2 and heparin. Eur J Biochem. 1999; 259:917–25. https://doi.org/10.1046/j.1432-1327.1999.00127.x PMID:10092882

67. Costell M, Gustafsson E, Aszódi A, Mörgelin M, Bloch W, Hunziker E, Addicks K, Timpl R, Fässler R. Perlecan maintains the integrity of cartilage and some basement membranes. J Cell Biol. 1999; 147:1109–22. https://doi.org/10.1083/jcb.147.5.1109 PMID:10579729

68. Titz B, Dietrich S, Sadowski T, Beck C, Petersen A, Sedlacek R. Activity of MMP-19 inhibits capillary-like formation due to processing of nidogen-1. Cell Mol Life Sci. 2004; 61:1826–33. https://doi.org/10.1007/s00018-004-4105-0 PMID:15241558

69. Rhodes DR, Yu J, Shanker K, Deshpande V, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 2004; 6:1–6. https://doi.org/10.1016/S1476-5586(04)80047-2 PMID:15068665

70. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45:W98–102. https://doi.org/10.1093/nar/gkx247 PMID:28407145

71. Chandrashekar DS, Bashel B, Balasubramanya SA, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BV, Varambally S. UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017; 19:649–58. https://doi.org/10.1016/j.neo.2017.05.002 PMID:28732212

72. Zhao Z, Zhang KN, Wang Q, Li G, Zeng F, Zhang Y, Wu F, Chai R, Wang Z, Zhang C, Zhang W, Bao Z, Jiang T. Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data for Chinese Glioma Patients. bioRxiv. 2020. https://doi.org/10.1101/2020.01.20.911982

73. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, Olsson I, Edlund K, Lundberg E, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015; 347:1260419. https://doi.org/10.1126/science.1260419 PMID:25613900

74. Thul PJ, Åkesson L, Wiking M, Mahdessian D, Geladaki A, Ait Blal H, Alm T, Asplund A, Björk L, Breckels LM, Bäckström A, Danielsson F, Fagerberg L, et al. A subcellular map of the human proteome. Science. 2017; 356:aal3321. https://doi.org/10.1126/science.aal3321 PMID:28495876

75. Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhor G, Benfeitas R, Arif M, Liu Z, Edfors F, Sanli K, von Feilitzen K, Oksvold P, et al. A pathology atlas of the human cancer transcriptome. Science. 2017; 357:eaaan2507. https://doi.org/10.1126/science.aan2507 PMID:28818916

76. Sjöstedt E, Zhong W, Fagerberg L, Karlsson M, Metsios N, Adori C, Oksvold P, Edfors F, Limiszewska A, Hikmet F, Huang J, Du Y, Lin L, et al. An atlas of the protein-coding genes in the human, pig, and mouse brain. Science. 2020; 367:eaay5947. https://doi.org/10.1126/science.aay5947 PMID:32139519

77. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, Benner C, Chanda SK. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019; 10:1523. https://doi.org/10.1038/s41467-019-09234-6 PMID:30944313

78. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork P, Jensen LJ, Mering C. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019; 47:D607–13. https://doi.org/10.1093/nar/gky1131 PMID:30476243

79. Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, Jensen LJ, von Mering C. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017; 45:D362–68. https://doi.org/10.1093/nar/gkw937 PMID:27924014

80. Franz M, Rodriguez H, Lopes C, Zuberi K, Montojo J, Bader GD, Morris Q. GeneMANIA update 2018. Nucleic Acids Res. 2018; 46:W60–64. https://doi.org/10.1093/nar/gky311 PMID:29912392

81. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017; 77:e108–10.
82. Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, Zhu J, Haussler D. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020; 38:675–78. 

https://doi.org/10.1038/s41587-020-0546-8

PMID: 32444850
### SUPPLEMENTARY MATERIALS

Supplementary Tables

**Supplementary Table 1. List of cancer types included in this study.**

| Abbreviation | Cancer Type                                      |
|--------------|--------------------------------------------------|
| ACC          | Adrenocortical carcinoma;                        |
| BLCA         | Bladder urothelial carcinoma;                    |
| BRCA         | Breast invasive carcinoma;                       |
| CESC         | Cervical squamous cell carcinoma;                |
| CHOL         | Cholangiocarcinoma;                              |
| COAD         | Colon adenocarcinoma;                            |
| DLBC         | Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; |
| ESCA         | Esophageal carcinoma;                            |
| GBM          | Glioblastoma multiforme;                         |
| HNSC         | Head and Neck squamous cell carcinoma;           |
| KICH         | Kidney Chromophobe;                              |
| KIRC         | Kidney renal clear cell carcinoma;               |
| KIRP         | Kidney renal papillary cell carcinoma;           |
| LGG          | Brain lower grade glioma;                        |
| OV           | Ovarian serous cystadenocarcinoma;               |
| MESO         | Mesothelioma;                                    |
| LIHC         | Liver hepatocellular carcinoma;                  |
| LUAD         | Lung adenocarcinoma;                             |
| LUSC         | Lung squamous cell carcinoma;                    |
| PAAD         | Pancreatic adenocarcinoma;                       |
| PRAD         | Prostate adenocarcinoma;                         |
| PCPG         | Pheochromocytoma and Paraganglioma;             |
| READ         | Rectum adenocarcinoma;                           |
| SARC         | Sarcoma;                                         |
| SKCM         | Skin Cutaneous Melanoma;                         |
| LAML         | Acute myeloid leukemia;                          |
| TGCT         | Testicular Germ Cell Tumors;                     |
| THCA         | Thyroid carcinoma;                               |
| THYM         | Thymoma;                                         |
| STAD         | Stomach adenocarcinoma;                          |
| UCEC         | Uterine Corpus Endometrial Carcinoma;            |
| UCS          | Uterine Carcinosarcoma;                          |
| UVM          | Uveal Melanoma.                                  |
Supplementary Table 2. Clinical information of the 9 glioma patients.

| Gender | Age | Tumor site       | Pathologic diagnosis                          |
|--------|-----|------------------|------------------------------------------------|
| Female | 37  | right insular lobe| Low grade glioma (WHO grade II)                |
| Man    | 64  | left temporal lobe| Diffuse glial tumor (WHO grade III-IV)         |
| Female | 57  | left parietal lobe| Glioblastoma (WHO grade IV)                   |
| Man    | 66  | left parietal lobe| High grade glioma (WHO grade IV)               |
| Man    | 48  | left parietal lobe| Glioblastoma (WHO grade IV)                   |
| Man    | 58  | left frontal lobe | WHO grade III-IV                               |
| Man    | 55  | left frontal lobe | WHO grade III-IV                               |
| Man    | 52  | left frontal lobe | Glioblastoma (WHO grade IV)                   |
| Man    | 63  | left frontal lobe | Diffuse glial tumor (WHO grade III)            |
Supplementary Table 3. The top100 NID1-related genes in gliomas.

| Gene symbol | Gene ID          | PCC  |
|-------------|------------------|------|
| FMO1        | ENSG0000010932.15| 0.84 |
| ABCA9       | ENSG00000154258.16| 0.81 |
| EDARADD     | ENSG00000186197.12| 0.81 |
| ENO1P1      | ENSG00000244457.2| 0.81 |
| AC026904.1  | ENSG00000233858.4| 0.81 |
| SCARA5      | ENSG00000168079.16| 0.80 |
| C1QTNF9     | ENSG00000240654.6| 0.80 |
| CILP        | ENSG00000138615.5| 0.80 |
| KERA        | ENSG00000139330.5| 0.80 |
| ADH1C       | ENSG00000248144.5| 0.80 |
| SULT1E1     | ENSG00000109193.10| 0.80 |
| RP11-567J20.1| ENSG00000253702.1| 0.80 |
| TNNT3       | ENSG00000130595.16| 0.79 |
| CYGB        | ENSG00000161544.9| 0.79 |
| FZD1        | ENSG00000157240.3| 0.79 |
| FABP4       | ENSG00000170323.8| 0.79 |
| RP11-199H2.2| ENSG00000282265.1| 0.79 |
| CAPN6       | ENSG00000077274.8| 0.79 |
| DPPA3P3     | ENSG00000270415.1| 0.79 |
| CYP1B1-AS1  | ENSG00000232973.11| 0.79 |
| RP11-1K3.1  | ENSG00000257281.1| 0.79 |
| PRG4        | ENSG00000116690.11| 0.79 |
| CDC42EP5    | ENSG00000167617.2| 0.79 |
| AP004372.1  | ENSG00000238117.1| 0.79 |
| RP11-1260E13.1| ENSG00000262920.5| 0.79 |
| RN7SKP282   | ENSG00000252633.1| 0.79 |
| UGT2B24P    | ENSG00000249956.4| 0.79 |
| RP11-351A20.1| ENSG00000261818.1| 0.79 |
| AADACL2-AS1 | ENSG00000242908.6| 0.79 |
| SNORA40     | ENSG00000212579.1| 0.79 |
| RNU6-748P   | ENSG00000207378.1| 0.79 |
| RP11-117D22.1| ENSG00000226938.1| 0.79 |
| P2RY10P2    | ENSG00000232168.2| 0.79 |
| RNA5SP307   | ENSG00000199733.1| 0.79 |
| RP11-204N11.2| ENSG00000258379.1| 0.79 |
| RP11-336A10.7| ENSG00000228685.1| 0.79 |
| SRP68P1     | ENSG00000266129.1| 0.79 |
| AC011523.2  | ENSG00000267968.1| 0.79 |
| RP11-146N18.1| ENSG00000267134.1| 0.79 |
| ZNF736P11Y  | ENSG00000215537.3| 0.79 |
| RP11-259O2.2| ENSG00000248597.1| 0.79 |
| ZBTB8OSP1   | ENSG00000183432.6| 0.79 |
| AC011193.1  | ENSG00000225582.1| 0.79 |
| CTLA4       | ENSG00000163599.14| 0.79 |
| CERS3       | ENSG00000154227.13| 0.78 |
| RP11-401O9.4| ENSG00000273388.1| 0.78 |
| PRAC1       | ENSG00000159182.4| 0.78 |
| RP11-359G22.2| ENSG00000230400.1| 0.78 |
| Gene          | ENSG     | Score |
|---------------|----------|-------|
| DCSTAMP       | ENSG00000164935.6 | 0.78  |
| AC093627.11   | ENSG00000239715.1 | 0.78  |
| AC064834.1    | ENSG00000224099.1 | 0.78  |
| RP11-392O17.1 | ENSG00000228536.1 | 0.78  |
| RP11-89H19.1  | ENSG00000205537.2 | 0.78  |
| AP000998.2    | ENSG00000227330.1 | 0.77  |
| RP11-401O9.3  | ENSG00000264067.1 | 0.77  |
| RP11-863P13.3 | ENSG00000261327.4 | 0.77  |
| PA2G4P1       | ENSG00000237828.1 | 0.77  |